Wells Fargo
STRO icon

Wells Fargo’s Sutro Biopharma STRO Stock Holding History

Wells Fargo’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450K Buy
+13,544
New +$422K ﹤0.01% 4706
2026
Q1 		– Sell
-100
Closed -$1.16K – 7443
2025
Q4 		$1.16K Buy
+100
New +$949 ﹤0.01% 6273
2025
Q3 		– Sell
-69
Closed -$495 – 7376
2025
Q2 		$495 Sell
69
-4,844
-99% -$39.6K ﹤0.01% 6374
2025
Q1 		$32K Sell
4,913
-361
-7% -$5.68K ﹤0.01% 5543
2024
Q4 		$97K Buy
5,274
+1,047
+25% +$32K ﹤0.01% 5217
2024
Q3 		$146K Buy
4,227
+41
+1% +$1.61K ﹤0.01% 4782
2024
Q2 		$123K Buy
4,186
+1,449
+53% +$57.3K ﹤0.01% 4811
2024
Q1 		$155K Buy
2,737
+420
+18% +$18.6K ﹤0.01% 4628
2023
Q4 		$99.4K Buy
2,317
+365
+19% +$11.6K ﹤0.01% 4901
2023
Q3 		$67.7K Sell
1,952
-806
-29% -$35.1K ﹤0.01% 5011
2023
Q2 		$128K Sell
2,758
-2,258
-45% -$112K ﹤0.01% 4877
2023
Q1 		$232K Buy
5,016
+4,447
+782% +$282K ﹤0.01% 4335
2022
Q4 		$46K Buy
569
+437
+331% +$30.4K ﹤0.01% 4902
2022
Q3 		$8K Sell
132
-143
-52% -$8.46K ﹤0.01% 5781
2022
Q2 		$14K Sell
275
-3,536
-93% -$198K ﹤0.01% 5618
2022
Q1 		$313K Sell
3,811
-1,411
-27% -$134K ﹤0.01% 4719
2021
Q4 		$777K Sell
5,222
-6,060
-54% -$1.09M ﹤0.01% 4316
2021
Q3 		$2.13M Sell
11,282
-2,735
-20% -$520K ﹤0.01% 3619
2021
Q2 		$2.61M Sell
14,017
-357
-2% -$69.9K ﹤0.01% 3449
2021
Q1 		$3.27M Buy
14,374
+8,099
+129% +$1.92M ﹤0.01% 3262
2020
Q4 		$1.36M Buy
6,275
+1,706
+37% +$282K ﹤0.01% 3790
2020
Q3 		$459K Buy
4,569
+1,501
+49% +$142K ﹤0.01% 4411
2020
Q2 		$238K Buy
3,068
+922
+43% +$88.5K ﹤0.01% 4808
2020
Q1 		$218K Buy
2,146
+204
+11% +$21.4K ﹤0.01% 4627
2019
Q4 		$213K Buy
1,942
+548
+39% +$56.5K ﹤0.01% 4916
2019
Q3 		$127K Buy
1,394
+246
+21% +$24.8K ﹤0.01% 5209
2019
Q2 		$130K Buy
1,148
+811
+241% +$89.4K ﹤0.01% 5191
2019
Q1 		$38K Buy
337
+7
+2% +$728 ﹤0.01% 5388
2018
Q4 		$30K Buy
+330
New +$39.8K ﹤0.01% 5680

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Wells Fargo's STRO Position: Q2 2026 in Review

Wells Fargo opened a new position in Sutro Biopharma (STRO) in Q2 2026: 13,544 shares worth $450K. The stake represents ﹤0.01% of the portfolio and ranks #4706 among its holdings. This is a return to the name: Wells Fargo previously reported a position in STRO as recently as Q4 2025.

Wells Fargo first reported a position in STRO in Q4 2018 and has held it in 29 quarters since. The position peaked at $3.27M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Wells Fargo held 13,544 shares of Sutro Biopharma worth $450K as of Q2 2026.
  • Sutro Biopharma was a new Wells Fargo position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4706 holding.
  • Wells Fargo first reported a position in Sutro Biopharma in Q4 2018 and has held it in 29 quarters since.
  • Wells Fargo's Sutro Biopharma position peaked at $3.27M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.